• About us
• Contact

Advertisement

Organisation › Details

Affinium Pharmaceuticals Inc.

Affinium Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovery and development of novel anti-infective medicines. The Affinium FASII antibacterial programs constitute a new antibiotic franchise with the potential for multiple products targeting the FASII pathway. These programs include a broad base of long-term intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors of a new class of antibiotics with a unique mechanism of action, targeting an underexploited pathway. Affinium's major investors include SV Life Science Advisors LLC, Genesys Capital Management, Forward Ventures, and Ontario Capital Growth Corporation. *

 

	Start	2003-01-01 renamed
	Predecessor	Integrative Proteomics Inc.
	Industry	proteomics
	Region	Toronto, ON
	Country	Canada
	Street	200 Front Street West Suite 3004, B.O. Box 31
	City	M5V 3K2 Toronto, ON
	Tel	+1-416-645-6613
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.